EurekaMag.com logo
+ Translate

Genome-scale study of Huntington's disease identifies potential drug targets


, : Genome-scale study of Huntington's disease identifies potential drug targets. Pharmacogenomics 14(2): 123-123


(PDF same-day service: $19.90)

Accession: 053395022

PMID: 23327572

DOI: 10.2217/pgs.12.209

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Miller, J.P.; Yates, B.E.; Al-Ramahi, I.; Berman, A.E.; Sanhueza, M.; Kim, E.; de Haro, M.; DeGiacomo, F.; Torcassi, C.; Holcomb, J.; Gafni, J.; Mooney, S.D.; Botas, J.; Ellerby, L.M.; Hughes, R.E., 2013: A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease. A genome-scale RNAi screen was performed in a mammalian cell-based assay to identify modifiers of mutant huntingtin toxicity. Ontology analysis of suppressor data identified processes previously implicated in Huntington's disease, including p...

O'Reilly, L.P.; Long, O.S.; Cobanoglu, M.C.; Benson, J.A.; Luke, C.J.; Miedel, M.T.; Hale, P.; Perlmutter, D.H.; Bahar, I.; Silverman, G.A.; Pak, S.C., 2015: A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency. α1-Antitrypsin deficiency (ATD) is a common genetic disorder that can lead to end-stage liver and lung disease. Although liver transplantation remains the only therapy currently available, manipulation of the proteostasis network (PN) by small mo...

Müller-Tidow, C.; Schwäble, J.; Steffen, Börn.; Tidow, N.; Brandt, B.; Becker, K.; Schulze-Bahr, E.; Halfter, H.; Vogt, U.; Metzger, R.; Schneider, P.M.; Büchner, T.; Brandts, C.; Berdel, W.E.; Serve, H., 2004: High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Novel high-throughput analyses in molecular biology allow sensitive and rapid identification of disease-related genes and drug targets. We have used quantitative real-time reverse transcription-PCR reactions (n = 23000) to analyze expression of al...

Seyhan, A.A.; Varadarajan, U.; Choe, S.; Liu, W.; Ryan, T.E., 2012: A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Neratinib (HKI-272) is a small molecule tyrosine kinase inhibitor of the ErbB receptor family currently in Phase III clinical trials. Despite its efficacy, the mechanism of potential cellular resistance to neratinib and genes involved with it rema...

Adamia, S.; Haibe-Kains, B.; Pilarski, P.M.; Bar-Natan, M.; Pevzner, S.; Avet-Loiseau, H.; Lode, L.; Verselis, S.; Fox, E.A.; Burke, J.; Galinsky, I.; Dagogo-Jack, I.; Wadleigh, M.; Steensma, D.P.; Motyckova, G.; Deangelo, D.J.; Quackenbush, J.; Stone, R.; Griffin, J.D., 2014: A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Despite new treatments, acute myeloid leukemia (AML) remains an incurable disease. More effective drug design requires an expanded view of the molecular complexity that underlies AML. Alternative splicing of RNA is used by normal cells to generate...

Levering, J.; Fiedler, T.; Sieg, A.; van Grinsven, K.W.A.; Hering, S.; Veith, N.; Olivier, B.G.; Klett, L.; Hugenholtz, J.; Teusink, B.; Kreikemeyer, B.; Kummer, U., 2016: Genome-scale reconstruction of the Streptococcus pyogenes M49 metabolic network reveals growth requirements and indicates potential drug targets. Genome-scale metabolic models comprise stoichiometric relations between metabolites, as well as associations between genes and metabolic reactions and facilitate the analysis of metabolism. We computationally reconstructed the metabolic network of...

Benhamed, M.; Martin-Magniette, M-Laure.; Taconnat, L.; Bitton, Fédérique.; Servet, C.; D.C.ercq, R.; D.M.yer, Börn.; Buysschaert, C.; Rombauts, Séphane.; Villarroel, R.; Aubourg, Sébastien.; Beynon, J.; Bhalerao, R.P.; Coupland, G.; Gruissem, W.; Menke, F.L.H.; Weisshaar, B.; Renou, J-Pierre.; Zhou, D-Xiu.; Hilson, P., 2008: Genome-scale Arabidopsis promoter array identifies targets of the histone acetyltransferase GCN5. We have assembled approximately 20 000 Arabidopsis thaliana promoter regions, compatible with functional studies that require cloning and with microarray applications. The promoter fragments can be captured as modular entry clones (MultiSite Gatew...

Telkar, S.; Kumar, H.Shivashankara.Santosh.; Deeplanaik, N.; Mahmood, R., 2014: Strategic genome-scale prioritization of unique drug targets: A case study of Streptococcus gordonii. The current reach of genomics extends facilitated identification of microbial virulence factors, a primary objective for antimicrobial drug and vaccine design. Many putative proteins are yet to be identified which can act as potent drug targets. T...

Ellis, J.A.; Munro, J.E.; Chavez, R.A.; Gordon, L.; Joo, J.E.; Akikusa, J.D.; Allen, R.C.; Ponsonby, A-Louise.; Craig, J.M.; Saffery, R., 2012: Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease. Juvenile Idiopathic Arthritis (JIA) is a complex autoimmune rheumatic disease of largelyunknown cause. Evidence is growing that epigenetic variation, particularly DNAmethylation, is associated with autoimmune disease. However, nothing is currently...

Kim, J-Hyun.; Cheong, H.Sub.; Sul, J.Hoon.; Seo, J-Meen.; Kim, D-Yeon.; Oh, J-Tak.; Park, K-Won.; Kim, H-Young.; Jung, S-Min.; Jung, K.; Cho, M.Jeng.; Bae, J.Seol.; Shin, H.Doo., 2015: A genome-wide association study identifies potential susceptibility loci for Hirschsprung disease. Hirschsprung disease (HSCR) is a congenital and heterogeneous disorder characterized by the absence of intramural nervous plexuses along variable lengths of the hindgut. Although RET is a well-established risk factor, a recent genome-wide associat...